Creative Planning
TCON

Creative Planning’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Creative Planning’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-125
Closed -$79K – 2020
2017
Q3 		$79K Hold
125
– – ﹤0.01% 1739
2017
Q2 		$60K Buy
+125
New +$76.2K ﹤0.01% 2381

Other funds holding TCON

NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
X-Square Capital
X-Square Capital Guaynabo, Puerto Rico $412M AUM 29.24% 1-Year Est. Return
QVT Financial
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Raymond James & Associates
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Creative Planning's TCON Position: Q4 2017 in Review

Creative Planning sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2017, closing a stake of 125 shares — an estimated $79K sold.

Creative Planning first reported a position in TCON in Q2 2017 and held it in 2 quarters. The position peaked at $79K in Q3 2017. 32 funds tracked by Wall St. Rank hold TCON as of Q4 2017.

  • Creative Planning reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Creative Planning sold 125 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $79K.
  • Creative Planning first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Creative Planning's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $79K in Q3 2017.
  • 32 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Creative Planning's 13F filing for Q4 2017, filed 17 Jan 2018.